LA JOLLA, Calif., Nov. 2, 2021 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the Avidity management team will be participating at the following
conferences:
Credit Suisse 30th Annual Healthcare
Conference
November
10th, 2021
Fireside Chat @ 2:40pm ET
4th Annual Evercore ISI HealthCONx
Conference
November
30th, 2021
Fireside Chat @ 10:05am ET
Live webcasts of each event, as well as an archived replay of
the webcasts following each event, will be available on the "Events
and Presentations" page in the "Investors" section of Avidity's
website at
https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCsTM). Avidity's
proprietary AOCs are designed to combine the specificity of
monoclonal antibodies with the precision of oligonucleotide
therapies to target the root cause of diseases previously
untreatable with RNA therapeutics. Avidity's lead product
candidate, AOC 1001, is designed to treat myotonic dystrophy type 1
(DM1). The FDA has cleared Avidity to proceed with the Phase 1/2
MARINATM trial of AOC 1001 in adults with DM1. Its
advancing and expanding pipeline also includes programs in
facioscapulohumeral muscular dystrophy (FSHD), Duchenne Muscular
Dystrophy (DMD), muscle atrophy and Pompe disease. The company is
planning for AOC 1044, the lead of three programs for the treatment
of DMD, and its AOC FSHD program to enter the clinic in 2022.
Avidity is also broadening the reach of AOCs beyond muscle tissues
through both internal discovery efforts and key partnerships as the
company continues to deliver on the RNA revolution. Avidity is
headquartered in La Jolla, CA. For
more information about our science, pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and Twitter.
Company Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301413250.html
SOURCE Avidity Biosciences, Inc.